<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - METHOTREXATE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>METHOTREXATE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#preTreatmentScreening" data-toggle="tab">Pre-treatment screening</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Severe Crohn's disease</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 25 mg once weekly until remission induced; maintenance 15 mg once weekly.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Maintenance of remission of severe Crohn's disease</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                10&#8211;25 mg once weekly.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Moderate to severe active rheumatoid arthritis</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                7.5 mg once weekly, adjusted according to response; maximum 20 mg per week.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Severe active rheumatoid arthritis</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection or by intramuscular injection or by subcutaneous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 7.5 mg once weekly, then increased in steps of 2.5 mg once weekly, adjusted according to response; maximum 25 mg per week.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Neoplastic diseases</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection or by intrathecal injection or by intra-arterial infusion or by intramuscular injection or by intravenous infusion or by mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                (consult product literature).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Severe psoriasis unresponsive to conventional therapy (specialist use only)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth or by intramuscular injection or by intravenous injection or by subcutaneous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 2.5&#8211;10 mg once weekly, then increased in steps of 2.5&#8211;5 mg, adjusted according to response, dose to be adjusted at intervals of at least 1 week; usual dose 7.5&#8211;15 mg once weekly, stop treatment if inadequate response after 3 months at the optimum dose; maximum 30 mg per week.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Methotrexate inhibits the enzyme dihydrofolate reductase, essential for the synthesis of purines and pyrimidines.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Avoid (teratogenic; fertility may be reduced during therapy but this may be reversible).</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>When used for malignancy, avoid in severe hepatic impairment&#8212;consult local treatment protocol for details.</p><p>Avoid with hepatic impairment in non-malignant conditions&#8212;dose-related toxicity.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>Reduce dose.</p>
            </section>
        
            <section class="generalInformation">
              <p>Risk of nephrotoxicity at high doses.</p><p>Avoid in severe impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Active infection (in non-malignant conditions)</li>
            <li>ascites</li>
            <li>immunodeficiency syndromes (in non-malignant conditions)</li>
            <li>significant pleural effusion</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>rare:</strong> Pneumonitis,
              </p>
              <p>
                <strong>notKnown:</strong> Abdominal discomfort, acne, alopecia, anaphylactic reactions, anorexia, arthralgia, blood disorders, changes in nail pigmentation, changes in skin pigmentation, chills, chronic pulmonary fibrosis, confusion, conjunctivitis, cystitis, diarrhoea, dizziness, drowsiness, dyspepsia, dysuria, ecchymosis, fever, furuncolosis, gastro-intestinal bleeding, gastro-intestinal ulceration, haematuria, headache, hepatotoxicity, hypotension, impotence, injection-site reactions, insomnia, interstitial pneumonitis, malaise, menstrual disturbances, mood changes, mucositis, myalgia, myelosuppresion, nausea, neurotoxicity, osteoporosis, paraesthesia, pericardial tamponade, pericarditis, photosensitivity, pleuritic pain, precipitation of diabetes, pruritus, pulmonary fibrosis, pulmonary oedema, rash, reduced libido, renal failure, Stevens-Johnson syndrome, telangiectasia, thrombosis, toxic epidermal necrolysis, toxic megacolon, urticaria, vaginitis, vasculitis, visual disturbance, vomiting,
              </p>
        
        
            <section class="advice">
              <p>In patients taking methotrexate for non-malignant conditions who experience side-effects, folic acid given on a different day from the methotrexate, may help to reduce the frequency of such side-effects.</p>
            </section>
            <section class="advice">
              <p>Withdraw treatment if stomatitis develops&#8212;may be first sign of gastro-intestinal toxicity.</p><p>Treatment with folinic acid (as calcium folinate) may be required in acute toxicity.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>Patients should be advised to avoid self-medication with over-the-counter aspirin or ibuprofen.</p><p>Patients should be counselled on the dose, treatment booklet, and the use of NSAIDs.</p>
            </section>
            <section class="generalPatientAdvice">
              <p>Patients and their carers should be warned to report immediately the onset of any feature of blood disorders (e.g. sore throat, bruising, and mouth ulcers), liver toxicity (e.g. nausea, vomiting, abdominal discomfort and dark urine), and respiratory effects (e.g. shortness of breath).</p>
            </section>
            <section class="patientResources">
                <h3>Methotrexate treatment booklets</h3>
              <p>Methotrexate treatment booklets should be issued where appropriate.</p><p>In <b>England</b>, <b>Wales</b>, and <b>Northern Ireland</b>, they are available for purchase from:</p><ul outputclass="organization">
            <li outputclass="thoroughfare">Gorse Street, Chadderton</li>
            <li outputclass="localityname">Oldham</li>
            <li outputclass="postalcode">OL9 9QH</li>
            <li outputclass="contactnumber">Tel: 0845 610 1112</li>
            </ul><p>GP practices can obtain supplies through their Local Area Team stores. </p><p>NHS Hospitals can order supplies from <xref format="html" href="http://www.nhsforms.co.uk">www.nhsforms.co.uk</xref>
            </p><p>or by emailing nhsforms@mmm.com.</p><p>In <b>Scotland</b>, treatment booklets can be obtained by emailing stockorders.dppas@theapsgroup.com or by fax on 0131 629 9967.</p><p>These booklets include advice for adults taking oral methotrexate for inflammatory conditions, and a section for recording results of blood tests and dosage information.</p>
            </section>
      </section>


      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
              <p>Note that the dose is a <b>weekly</b> dose. To avoid error with low-dose methotrexate, it is recommended that:</p><ul>
            <li>the patient is carefully advised of the <b>dose</b> and <b>frequency</b> and the reason for taking methotrexate and any other prescribed medicine (e.g. folic acid);</li>
            <li>only one strength of methotrexate tablet (usually 2.5&#8239;mg) is prescribed and dispensed;</li>
            <li>the prescription and the dispensing label clearly show the dose and frequency of methotrexate administration;</li>
            <li>the patient is warned to report immediately the onset of any feature of blood disorders (e.g. sore throat, bruising, and mouth ulcers), liver toxicity (e.g. nausea, vomiting, abdominal discomfort, and dark urine), and respiratory effects (e.g. shortness of breath).</li>
            </ul>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            <xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref>
          </li>
          <li>
            diarrhoea
          </li>
          <li>
            extreme caution in blood disorders (avoid if severe)
          </li>
          <li>
            peptic ulceration
          </li>
          <li>
            photosensitivity&#8212;psoriasis lesions aggravated by UV radiation (skin ulceration reported)
          </li>
          <li>
            risk of accumulation in pleural effusion or ascites&#8212; drain before treatment
          </li>
          <li>
            ulcerative colitis
          </li>
          <li>
            ulcerative stomatitis
          </li>
        </ul>
        <ul>
          <li>
            <p>Bone marrow suppression can occur abruptly; factors likely to increase toxicity include advanced age, renal impairment, and concomitant use with another anti-folate drug (e.g. trimethoprim). A clinically significant drop in white cell count or platelet count calls for immediate withdrawal of methotrexate and introduction of supportive therapy.</p>
          </li>
          <li>
            <p>Liver cirrhosis reported. Treatment should not be started or should be discontinued if any abnormality of liver function tests or liver biopsy is present or develops during therapy. Abnormalities can return to normal within 2 weeks after which treatment may be recommenced if judged appropriate.</p>
          </li>
          <li>
            <p>Pulmonary toxicity may be a special problem in rheumatoid arthritis (patient to seek medical attention if dyspnoea, cough or fever); monitor for symptoms at each visit&#8212;discontinue if pneumonitis suspected.</p>
          </li>
          <li>
            <p>Withdraw treatment if stomatitis develops&#8212;may be first sign of gastro-intestinal toxicity.</p>
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Effective contraception required during and for at least 3 months after treatment in men or women.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>In view of reports of blood dyscrasias (including fatalities) and liver cirrhosis with low-dose methotrexate patients should:</p><ul>
            <li>have full blood count and renal and liver function tests repeated every 1&#8211;2 weeks until therapy stabilised, thereafter patients should be monitored every 2&#8211;3 months.</li>
            <li>be advised to report all symptoms and signs suggestive of infection, especially sore throat<p>Local protocols for frequency of monitoring may vary.</p>
            <p>Treatment with folinic acid (as calcium folinate) may be required in acute toxicity.</p>
            </li>
            </ul>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <p>Not licensed for use in severe Crohn's disease.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Folinic acid following methotrexate administration helps to prevent methotrexate-induced mucositis and myelosuppression.</p>
            </section>
      </section>




      <section class="tab-pane" id="preTreatmentScreening">
        <h2>Pre-treatment screening</h2>

            <section class="preTreatmentScreening">
              <p>Exclude pregnancy before treatment.</p>
            </section>
            <section class="preTreatmentScreening">
              <p>Patients should have full blood count and renal and liver function tests before starting treatment.</p>
            </section>
      </section>





      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of METHOTREXATE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            solution for injection,
            oral suspension,
            oral solution,

            <div id="PHP74796"><a href="../medicinalForm/PHP74796.html" data-target="#PHP74796" data-action="load">Tablet</a></div>
            <div id="PHP75077"><a href="../medicinalForm/PHP75077.html" data-target="#PHP75077" data-action="load">Solution for injection</a></div>
            <div id="PHP74873"><a href="../medicinalForm/PHP74873.html" data-target="#PHP74873" data-action="load">Solution for infusion</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
